Clinical Efficacy Of Bifidobacteria BB-12 On Infantile Diarrhea

Objective:To investigate the efficacy and safety of Bifidobacterium BB-12 in the treatment of diarrhea in infants and young children,and the effect on the intestinal flora and short-chain fatty acids.Methods:From December 2015 to August 2016,120 children with diarrhea who were hospitalized in the Department of Pediatric Gastroenterology at the First Hospital of Jilin University were randomly divided into 3groups: Bifidobacterium BB-12 in treatment group and Bacillus subtilis duplex living bacterium positive control group and the placebo group,40 cases in each group,while collecting baseline,feces at 1,3,and 5 days after treatment at different time points.Each group of patients corresponding to the application of the corresponding drug,with montmorillonite and oral or intravenous rehydration therapy,compared the clinical efficacy of each group of cases and fecal intestinal flora and short-chain fatty acids were analyzed.Results:1.There was no significant difference in age,gender between children in each group(P>0.05).There was no significant difference in stool frequency,concomitant symptoms,and laboratory examination between the groups(P>0.05).2.In terms of curative effect,the effective rate and effective rate in the treatment group were 37.50% and 52.50% respectively,in the positive control group 42.50% and 42.50%,and in the placebo group17.50% and 52.50%,respectively.The difference was statistically significant(P< 0.05),the difference between the treatment group and the positive control group was not statistically significant(P> 0.05).3.Stool frequency: 4 days treatment group(3.10 ± 1.41)times / d,positive control group(3.05 ± 1.63)times / d,placebo group(3.93 ±1.91)times / d;7 days treatment group(1.45 ± 0.64 times / d,positive control group(1.43 ± 0.90)times / d,placebo group(1.95 ± 1.30)times /d,3 groups were significantly reduced compared with before treatment,the difference was statistically significant(P <0.05).However,there was no significant difference between the treatment group and the positive control group(P>0.05),and there was a significant difference between the treatment group and the placebo group(P<0.05).4.Three groups after treatment in children with diarrhea turnaroundtime,the treatment group,positive control group and the placebo group,respectively(4.20 + 1.32),(4.40-1.37)d,d(5.18 + 1.57)d,three groups was statistically significant difference(P < 0.05),but the treatment group compared with the positive control group,there was no statistically significant difference(P > 0.05).5.There were no consistent changes in the level of intestinal flora and short-chain fatty acids at different time points in the three groups of patients.The addition of probiotic bacteria at the genus level was more diversified.Conclusion:Bifidobacterium BB-12 was safe and effective in the treatment of diarrhea in infants and young children.There was no consistent change in the levels of intestinal flora and short-chain fatty acids,and the addition of probiotics at the genus level was more diversified.